Tranexamic Acid for Hemorrhagic Stroke

Current Evidence on TXA in Hemorrhagic Stroke

Clinical trials have shown that TXA can reduce hematoma expansion in ICH, but this has not consistently translated to improved clinical outcomes or reduced mortality, as reported by the American Medical Association 1, 2
The American Heart Association suggests that while TXA appears to be safe with no significant increase in single thromboembolic events, there may be an increased risk of combined ischemic events, although this is not consistently demonstrated across studies 2

The American College of Cardiology indicates that TXA may be beneficial when administered very early after ICH onset, particularly in hyperacute presentations, with potential benefits in reducing rebleeding and hematoma expansion 2
The use of TXA in specific ICH populations, such as NOAC-associated ICH, hyperacute ICH presentations, and antiplatelet-associated ICH, is being investigated, with preliminary evidence suggesting potential benefits in these groups 2

Early administration of TXA, ideally within 3-6 hours of symptom onset, is crucial for potential benefits, as emphasized by medical guidelines 3
Administration of TXA after 3 hours post-injury in trauma may increase risk of death due to bleeding, highlighting the importance of timely intervention 3

Standard dosing used in most ICH trials consists of a 1g loading dose over 10 minutes, followed by 1g infusion over 8 hours, as recommended by clinical guidelines 3
Higher doses of TXA are associated with increased risk of seizures, underscoring the need for careful dosing considerations 3

TXA has been reported as a case-based treatment for intravenous rtPA-associated hemorrhage in ischemic stroke patients, with potential benefits in reducing hematoma expansion and improving outcomes 4

Ongoing trials are evaluating TXA in specific ICH populations, including ICH associated with direct oral anticoagulants, hyperacute ICH presentations, and antiplatelet-associated ICH, with the goal of better defining its role in these contexts 2